CINCINNATI, OH, June 07, 2018 (GLOBE NEWSWIRE) -- Callitas (CSE: LILY, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”), an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, announced today that James Thompson will assume the position of President and Chief Executive Officer. For the prior six months, Mr. Thompson has served as Interim President and CEO in the absence of Gary Thompson, who stepped down for health reasons in December 2017. During the June 4, 2018, Board of Directors meeting, the decision was made for James to replace Gary at the helm of the Company.
“We continue to wish Gary best wishes and a complete recovery and we appreciate all his outstanding contributions while leading Callitas,” said Board Member, William Rodgers. “The entire Board has been impressed with James’ ongoing interim leadership of the Company and in recognition of his hard work and determination to continue to strategically build Callitas, we elevated him to the role of President and CEO. We look forward to where and how he expands the products and offerings of the Company. He is a strong business leader and the right fit for Callitas as the Company reaches new levels of expansion.”
“I look forward to building on what previous management, the Board of Directors and Gary personally has accomplished while CEO, as well as the progress we have made during the last few months,” said Mr. Thompson. “We have many exciting products and business developments in the pipeline that should benefit the Company and its shareholders long term.”
Prior to being named Interim President and CEO while Gary took a leave of absence, James served as the Chief Operating Officer of Callitas Health, Inc. James has a Bachelor of Science in biomedical engineering, with a double major in finance from Washington University in St. Louis, MO, and an Executive MBA from Xavier University in Cincinnati, OH.
Mr. Thompson added, “The Company has also made strides in continuing its OTC and CannaMint product development. New partnerships and advancements have set the stage for the Company to announce a number of new business initiatives during the upcoming weeks.”
About Callitas Health: Formed in early 2015, Callitas Health Inc. is an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, focused on developing innovative technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J’s LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive(www.toconceive.com), and is in the research and development and business development process for its other OTC products, CannaMint strips and orphan drug technologies. For more information visit www.callitas.com.
Contacts:
Callitas Health:
James Thompson, CEO, or
Callitas Investor Relations
Phone: +1 (859) 868-3131
TraDigitalIR:
Investor Relations – Kevin McGrath, Managing Director
Phone: +1 (646) 418-7002
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval and the commercialization of the rights to the Company’s biomedical & drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.thecse.com. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.
Notice regarding investigational devices: CannaMint Strips, C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.
Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements.